Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Difluprednate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.64 |
| ▸ | PGR | P06401 | 7/20 | 0.64 |
| ▸ | AR | P10275 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difluprednate SCHEMBL5486757 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL14339608 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL19961204 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL9954379 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL5486753 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL1276671 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL23343379 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL1276669 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL20769772 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR | |
| Difluprednate SCHEMBL4580 | 1.00 | HIF1A (1.00) | HIF1ALMNANPSR1CYP3A4PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14605 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144892-A1 | METHOD OF REDUCING CST FLUCTUATION IN NEOVASCULAR AMD BY A RECOMBINANT ADENO-ASSOCIATED VIRUS | ADVERUM BIOTECHNOLOGIES, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | claimed |
| US-12599556-B2 | Ophthalmic compositions | BIOTHERAVISION INC. (US) | 2026-04-14 | — | — | US | claimed |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | claimed |
| EP-4689184-A1 | IMMUNE LANDSCAPE SIGNATURES FOR OCULAR INFLAMMATION | Adverum Biotechnologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| CN-1073859-A | Regulate the compositions of wrinkle of skin and/or atrophoderma | RICHARDSON VICKS INC (US) | 1993-07-07 | — | — | CN | claimed |
| WO-1993010756-A1 | USE OF SALICYLIC ACID FOR REGULATING SKIN WRINKLES AND/OR SKIN ATROPHY | RICHARDSON-VICKS, INC. (US) | 1993-06-10 | — | — | WO | claimed |
| WO-1993010755-A1 | COMPOSITIONS FOR REGULATING SKIN WRINKLES AND/OR SKIN ATROPHY | RICHARDSON-VICKS, INC. (US) | 1993-06-10 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| US-4970206-A | TRANSDERMAL DRUG DELIVERY | MERCK & CO., INC. (US) | 1990-11-13 | — | — | US | claimed |
| US-4427670-A | CONTAINING CORTICOSTEROID, PHOSPHATIDE, AND BUTYLHYDROXYANISOLE, OR BUTYLHYDROXYTOLUENE | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1984-01-24 | — | — | US | claimed |
| US-4376767-A | ANTIBIOTICS AND PHARMACEUTICALS | MERCK & CO., INC. (US) | 1983-03-15 | — | — | US | claimed |
| EP-0055870-A1 | Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-07-14 | — | — | EP | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
| US-4279900-A | ANTIINFLAMMATORY | INTREX RESEARCH CORPORATION (US) | 1981-07-21 | — | — | US | claimed |